CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans

Vaccine

Volumn 18, Issue 18, 2000, Pages 1920-1924

  Davis, Heather L ^a,b   Suparto, Irma ^c   Weeratna, Risini ^a   Jumintarto, ^d   Iskandriati, Diah ^c   Chamzah, Siti ^a   Ma'Ruf, Amir ^d   Nente, Citrakasih ^d   Pawitri, Dyah ^c   Krieg, Arthur M ^e   Heriyanto, ^d   Smits, Willie ^d   Sajuthi, Dondin ^c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c BOGOR AGRICULTURAL UNIVERSITY   (Indonesia)

^d Kalimantan   (Indonesia)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

Adjuvant; Hepatitis B vaccine; Infectious immunity virus; Non human primate

Indexed keywords

ADJUVANT; DNA; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

ARTICLE; CPG ISLAND; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; APE DISEASES; CPG ISLANDS; DNA; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNE TOLERANCE; OLIGODEOXYRIBONUCLEOTIDES; PONGO PYGMAEUS;

EID: 17944402906     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00443-0     Document Type: Article

References (17)

1. Davis H.L., Weeratna R., Waldschmidt T.J., Schorr J., Krieg A.M. CpG DNA is a potent adjuvant in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:1998;870-876.
2. Maynard J.E., Hartwell W.V., Berquist K.R. Hepatitis-associated antigen in chimpanzees. J. Infec. Dis. 123:1971;660-664.
3. Norder H., Ebert J.W., Fields H.A., Mushahwar I.K., Magnius L.O. Complete sequencing of a gibbon hepatitis B virus genome reveals a unique genotype distantly related to the chimpanzee hepatitis B virus. Virology. 218:1996;214-223.
4. Reerink-Brongers E.E., Reesink H.W., Brummelhuis H.G.J., et al. Preparation and evaluation of heat-inactivated HBsAg as a vaccine against hepatitis B. Szmuness W., Alter H.J., Maynard J.E. Viral hepatitis. 1982;437-450 The Franklin Institute Press, Philadelphia.
5. Buynak E.B., Roehm R.R., Tytell A.A., Bertland A.U., Lampson G.P., Hilleman M.R. Development and chimpanzee testing of a vaccine against human hepatitis B. Proc. Soc. Exp. Biol. Med. 151:1976;694-700.
6. Guan R. Comparison of the immunogenicity of the 5 μg dose and 10 μg dose MSD rDNA hepatitis B vaccine (Hepavac II). Epidemiol. News Bull. 15:1989;24-26.
7. Jilg W., Lorbeer B., Schmidt M., Wilske B., Zoulek G., Deinhardt F. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet. Nov. 24:1984;1174-1175.
8. Coates R.A., Halliday M.L., Rankin J.G., et al. Immunogenicity and safety of a yeast-derived recombinant DNA hepatitis B vaccine in health care workers. Zuckerman A.J. Viral hepatitis and liver disease. 1988;1038-1042 Alan R. Liss, New York.
9. Yano M., Tashiro A. Clinical evaluation of recombinant yeast-derived hepatitis B vaccine. Zuckerman A.J. Viral hepatitis and liver disease. 1988;1050-1052 Alan R. Liss, New York.
10. Hollinger F.B., Troisi C.L., Pepe P.E. Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. J. Infec. Dis. 153:1986;156-159.
11. Recommendations of the Immunization Practices Advisory Committee. Update on hepatitis B prevention. MMWR. 36:1987;353.
12. Winter A.P., Follett E.A., McIntyre J., Stewart J., Symington I.S. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine. 12:1994;771-772.
13. Jungers P., Devillier P., Salomon H., Cerisier J.E., Courouce A.M. Randomized placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet. 344:1994;856-857.
14. Loinaz C., De Juanes J.R., Gonzalez E.M., et al. Hepatitis B vaccination results in 140 liver transplant patients. Hepato-Gastroenterology. 44:1997;235-238.
15. Alper C.A., Kruskall M.S., Marcus-Bagley D., et al. Genetic prediction of nonresponse to hepatitis B vaccine. New Eng. J. Med. 321:1989;708-712.
16. Hervas-Stubbs S., Berasain C., Golvano J.J., et al. Overcoming class II-linked non-responsiveness to hepatitis B vaccine. Vaccine. 12:1994;867-871.
17. Kruskall M.S., Alper C.A., Awdeh Z., Yunis E.J., Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: Inheritance patterns in families. J. Exp. Med. 175:1992;495-502.